MedTrace Logo

Resveratrol and Huntington Disease

NCT02336633 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2020-02-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate the therapeutic potential of Resveratrol on the caudate volume in HD patients, using volumetric MRI.

Conditions

  • Huntington Disease

Interventions

DIETARY_SUPPLEMENT

Resveratrol

2 capsules of 20mg in the morning and in the evening (4 capsules in total/day = 80mg/day) every day during 1 year

OTHER

Placebo

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Fanny Mochel, MD, PhD · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2019-10-31
Completion
2020-01-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02336633 on ClinicalTrials.gov